Accuray Inc is a leading innovator in cancer treatment technologies, primarily focusing on advanced radiation therapy solutions. The company specializes in the development of systems that deliver precise and targeted radiation to tumors, aiming to maximize therapeutic efficacy while minimizing damage to surrounding healthy tissue. Accuray's flagship products, including the CyberKnife and TomoTherapy systems, are designed to improve patient outcomes through increased accuracy and flexibility in treatment planning. Through its commitment to innovative engineering and clinical excellence, Accuray plays a significant role in enhancing the landscape of cancer care. Read More
Medical technology, infection control systems, oncology radiotherapy solutions, and diagnostics innovation remain key healthcare growth themes heading into 2026—and CS Diagnostics Corp. (OTCQB: CSDX) is positioning itself at the intersection of both.
San Francisco, CA – October 3, 2025 – In a move set to redefine the landscape of radiation oncology, Leo Cancer Care officially introduced its groundbreaking Upright Photon Therapy System, "Grace," at the ASTRO 2025 meeting in San Francisco on September 28, 2025. This innovative system challenges decades of conventional practice by
Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a Phase 1 study of its lead product, JNJ-1900 (NBTXR3), in patients with locally advanced esophageal adenocarcinoma. This pivotal development, revealed
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
